APA (7th ed.) Citation

Tweehuysen, L., Huiskes, V., van den Bemt, B., Vriezekolk, J., Teerenstra, S., van den Hoogen, F., . . . den Broeder, A. (2018). FRI0127 Open-label non-mandatory transitioning from originator etanercept to biosimilar sb4: 6-month results from a controlled cohort study. Annals of the rheumatic diseases, 77(Suppl 2), 608. https://doi.org/10.1136/annrheumdis-2018-eular.2592

Chicago Style (17th ed.) Citation

Tweehuysen, L., V.J.B Huiskes, B.J.F van den Bemt, J.E Vriezekolk, S. Teerenstra, F.H.J van den Hoogen, C.H van den Ende, and A.A den Broeder. "FRI0127 Open-label Non-mandatory Transitioning from Originator Etanercept to Biosimilar Sb4: 6-month Results from a Controlled Cohort Study." Annals of the Rheumatic Diseases 77, no. Suppl 2 (2018): 608. https://doi.org/10.1136/annrheumdis-2018-eular.2592.

MLA (9th ed.) Citation

Tweehuysen, L., et al. "FRI0127 Open-label Non-mandatory Transitioning from Originator Etanercept to Biosimilar Sb4: 6-month Results from a Controlled Cohort Study." Annals of the Rheumatic Diseases, vol. 77, no. Suppl 2, 2018, p. 608, https://doi.org/10.1136/annrheumdis-2018-eular.2592.